Protection of chickens against infectious bronchitis virus with a multivalent DNA vaccine and boosting with an inactivated vaccine.
- Author:
Fang YAN
1
;
Yujun ZHAO
;
Yongting HU
;
Jianyang QIU
;
Wenxin LEI
;
Wenhui JI
;
Xuying LI
;
Qian WU
;
Xiumin SHI
;
Zhong LI
Author Information
- Publication Type:Original Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords: IBV; multivalent DNA vaccine; prime-boost
- MeSH: Aging; Animals; Antibodies, Viral/blood; Cell Proliferation; Chickens; Coronavirus Infections/prevention & control/*veterinary/virology; Immunization, Secondary/veterinary; Infectious bronchitis virus/*immunology; Poultry Diseases/*prevention & control/virology; T-Lymphocyte Subsets/cytology/physiology; Vaccines, DNA/immunology; Vaccines, Inactivated/immunology; Viral Vaccines/*immunology
- From:Journal of Veterinary Science 2013;14(1):53-60
- CountryRepublic of Korea
- Language:English
- Abstract: The protective efficacy of DNA plasmids encoding avian infectious bronchitis virus (IBV) S1, N, or M protein was investigated in chickens. Chickens were inoculated monovalently (with plasmid pVAX1-16S1, pVAX1-16M, or pVAX1-16N alone) or multivalently (combination of the three different plasmids, pVAX1-16S1/M/N). A prime-boost immunization protocol against IBV was developed. Chickens were immunized with the multivalent DNA vaccine twice and then boosted with an inactivated vaccine once. Antibody titers of the chickens immunized with pVAX1-16S1/M/N were much higher than those of the monovalent groups (p < 0.01). A protective rate up to 90% was observed in the pVAX1-16S1/M/N group. The serum antibody titers in the prime-boost birds were significantly higher than those of the multivalent DNA vaccine group (p < 0.01) but not significantly different compared to the inactivated vaccine group at 49 days of age. Additionally, the prime-boost group also showed the highest level of IBV-specific cellular proliferation compared to the monovalent groups (p < 0.01) but no significant difference was found compared to the multivalent DNA vaccine group, and the prime-boost group completely protected from followed viral challenge.
